@article{article, title  = {{Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer}},

 publisher = {{American Association for Cancer Research}},

 url = {{}},

 year = {{2010}},

 month = {{12}},

 author = {{Martin M and Mackey J and Pienkowski T and Rolski J and Guastalla J-P and Sami A and Glaspy J and Juhos E and Wardley A and Fornander T and Hainsworth J et al}},

 doi = {{10.1158/0008-5472.sabcs10-s4-3}},

 journal = {{General Session Abstracts}},

 note = {{Accessed on 2025/10/10}}}